Shares of Intra-Cellular Plummet in Thursday's Trading Session

Shares of Intra-Cellular Therapies plummeted on Thursday as the biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful.
Author:
Publish date:

Shares of Intra-Cellular Therapies (ITCI) - Get Report plummeted on Thursday as biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful. The drug failed to reduce patients' schizophrenia symptoms when compared to a placebo. SunTrust subsequently downgraded Intra-Cellular's stock to NEUTRAL from BUY and cut its price target to $15 from $60 based on the trial results. Leerink also slashed its price target to $29 from $95, but said the recent selloff was overdone.

Employees of TheStreet are restricted from trading individual securities.